Cervical Cancer News and Research

RSS

Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix is the lower, narrow end of the uterus. Also known as the womb, the uterus is where a baby grows when a woman is pregnant. The cervix connects the upper part of the uterus to the vagina (birth canal).

Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

Summer Academy Meeting highlights benefits of HPV, Herpes Zoster vaccines

Vaccines have a long history of successfully preventing disease and, in effect, improving the lives of countless Americans. Now, two serious diseases - human papillomavirus (HPV) and herpes zoster - could become a thing of the past as people better understand the safety and efficacy of vaccines to prevent these serious viral infections in specific populations.

6 Aug 2010

Advaxis receives India’s DCGI approval for ADXS11-001 Phase II clinical trial for cervical cancer

Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received formal permission from the Drugs Controller General India (DCGI) to conduct a Phase II clinical trial of ADXS11-001, the Company's flagship drug construct, among 110 women with advanced, metastatic cervical cancer that has progressed subsequent to treatment with cytotoxic therapy. 55 women will receive ADXS11-001 alone, 55 will receive a combined regimen of both ADXS11-001 and cytotoxic therapy.

4 Aug 2010

Survey on administrating human papillomavirus vaccine for cervical cancer prevention

The vast majority of pediatricians and family physicians nationally are offering the human papillomavirus (also called HPV) vaccine, though fewer physicians are strongly encouraging it for 11- to 12-year-old girls as recommended by national guidelines, according to a survey in the September issue of Pediatrics, the journal of the American Academy of Pediatrics.

3 Aug 2010

Merck reports strong bottom-line performance in second quarter

Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.

2 Aug 2010

ACS CAN report finds nearly half of all states falling short on legislative solutions to prevent, fight cancer

Nearly half of all states are falling short on legislative solutions to prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN). However, despite budget crises in several states, some state lawmakers still made positive progress in the fight against a disease that will kill an estimated 569,000 people in the United States this year.

29 Jul 2010

CPRIT awards UH $2.4 million for new multidisciplinary research

The University of Houston (UH) received a $2.4 million grant to fund the most promising young cancer researchers who are working at the cutting-edge of a new multidisciplinary approach to fighting cancer.The award is part of the latest round of grant disbursements from the Cancer Prevention and Research Institute of Texas (CPRIT), which oversees the state's new billion-dollar war on cancer. It is UH's second CPRIT grant, and the first in the science and engineering fields.

28 Jul 2010

Zetiq reports self declaration CE mark of conformity for cervical cancer diagnostic kit

Zetiq Technologies Ltd., a subsidiary of Bio-Light Ltd., reports that it has fulfilled the essential requirements towards issuing a self declaration CE mark of conformity for its diagnostic product for identification of cervical cancer in cytological specimens.

27 Jul 2010

Einstein scientists awarded $4.1M to test microbicide Carraguard against HPV

The National Cancer Institute has awarded Albert Einstein College of Medicine of Yeshiva University $4.1 million to test the microbicide Carraguard- against the human papillomavirus, which causes cervical cancer. The research will evaluate the efficacy of Carraguard- - a clear gel made from the seaweed derivative carrageenan - in preventing new HPV infections in women.

26 Jul 2010

An overview of AAPM annual meeting

AAPM is the premier organization in medical physics, a broadly-based scientific and professional discipline encompassing physics principles and applications in medicine and biology. Its membership includes medical physicists who specialize in research that develops cutting-edge technologies and board-certified clinical medical physicists who apply these technologies in community hospitals, clinics, and academic medical centers.

16 Jul 2010

Cervical cancer vaccine could reduce number of cases from 3,000 to less than 700 every year

The cervical cancer vaccine could prevent even more cases of the disease in England than previously thought, UK scientists have found.

15 Jul 2010

Highlights of AAPM 52nd meeting

The 52nd meeting of the American Association of Physicists in Medicine (AAPM) convenes from July 18 - 22, 2010 in Philadelphia, PA.

14 Jul 2010

QIAGEN's digene HPV Test improves cervical cancer control: Study

A study released today "online first" in Cancer Causes & Control demonstrates that human papillomavirus testing, using QIAGEN's digene HPV Test, improved cervical cancer control compared to routine Pap (cytology) testing among 50,000 women across Mexico, the first country in Latin America to implement a national screening program for the high-risk types of HPV that can cause cervical cancer.

From QIAGEN Manchester Limited 13 Jul 2010

OvaGene Oncology completes license agreements with key Norwegian cancer researchers

OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today that it has completed license agreements with key Norwegian cancer researchers. The agreements allow OvaGene to validate two new promising genomic technologies with the intention of developing these into clinical laboratory tests.

13 Jul 2010

Vaccine manufacturers may be able to produce lower-cost HPV vaccines, say researchers

Vaccine manufacturers in India and other developing countries may be able to produce a lower-cost HPV vaccine in spite of the complicated array of patent protections on the technology, say researchers at the Duke Institute for Genome Sciences & Policy. At a cost of at least $300 for the three-dose regimen, the blockbuster HPV vaccines, including Gardasil- from Merck and Cervarix- from GlaxoSmithKline, are some of the most expensive ever introduced.

12 Jul 2010

HPV DNA testing for precancer, cervical cancer is more sensitive than cytology testing: Study

HPV DNA testing for precancers and cervical cancers is over 50 per cent more sensitive than cytology testing for the same conditions a community-based study in Mexico has revealed. Results of the largest HPV DNA primary screening study ever to be performed in a Latin American country point to the readiness of HPV DNA testing for large-scale implementation in Mexico and are published online today (8 July 2010) in Cancer, Causes and Controls.

9 Jul 2010

Screening for HPV genotypes 16 and 18 helps detect cervical pre-cancer missed by Pap test

Roche today announced that data from the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) U.S. registration trial of over 47,000 women demonstrate that two human papillomavirus genotypes, HPV 16 and HPV 18, can identify those women with cervical pre-cancer missed by cytologic examination with a Papanicolau (Pap) test.

From Roche Sequencing and Life Science 9 Jul 2010

Clinical performance data of Cervista HPV HR presented at International Papillomavirus Conference

Hologic, Inc., a leading women's healthcare company, today announced that final data analysis from the first large-scale independent evaluation of clinical performance of Cervista HPV HR compared to Hybrid Capture 2, were presented in Montreal, Canada, at the 26th International Papillomavirus Conference. Cervista HPV HR is a diagnostic test for the detection of 14 high-risk human papillomavirus types.

8 Jul 2010

QIAGEN receives CE conformity marking for careHPV Test

QIAGEN has completed European certification of its careHPV™ Test to bring human papillomavirus (HPV) testing to public-health programs in low-resource, developing countries, the company announced today at the International Papillomavirus Conference in Montreal, Canada. The CE conformity marking ("Conformite Europeenne") certifies that the careHPV Test has met European Union consumer safety and health requirements, allowing the test to be distributed in developing countries that recognize the CE mark.

From QIAGEN Manchester Limited 7 Jul 2010

Hologic enters definitive agreement to acquire Sentinelle Medical

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that it has entered into a definitive agreement to acquire Sentinelle Medical Inc., a leading provider of Magnetic Resonance Imaging (MRI) breast coils, tables and visualization software.

From Hologic, Inc. 7 Jul 2010

International conference focuses on HPV's impact on women

Scientists, clinicians and public health leaders from around the world are gathered in Montreal this week for the 26th International Papillomavirus Conference where they hope to generate awareness about human papillomavirus, Canwest News Service/Gazette reports (Martin/McCallum, 7/4).

7 Jul 2010